Regina F. Gandour-Edwards, M.D., M.H.S., M.S.
Clinical Interests
Regina Gandour-Edwards' expertise is in general surgical pathology with an emphasis on urologic
cancers and head/neck cancers. She is leader of the Cancer Center Biorepository and has recently
published studies relative to patient consenting issues and specimen quality in breast cancer. She
has a joint appointment in Urology and has several years of collaboration with the prostate cancer
program involving mechanisms of prostate cancer initiation and progression.
Title
Professor
Professor, Department of Pathology and Laboratory Medicine
Specialty
Department
Division
Center/Program Affiliation
Address/Phone
Surgical Pathology, Cancer, Pathology and Laboratory Medicine, Pathology - Anatomic
Pathology and Laboratory Medicine
Anatomic Pathology
UC Davis Comprehensive Cancer Center
Pathology Building, 4400 V St. Sacramento, CA 95817
Phone: 916-734-2525
Additional Phone
Phone: 916-734-2571
Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education
M.D., UC Davis School of Medicine, Sacramento, California, 1985
B.S., Georgetown University, Washington, District of Columbia, 1969
Residency
Board Certifications
Professional Memberships
University of California, Davis Medical Center, Sacramento, California, 1985-90
American Board of Pathology, Anatomic and Clinical Pathology, 1990
College of American Pathologists
International Society for Biological and Environmental Repositories
International Society of Urologic Pathology
United States and Canadian Academy of Pathology
Select Recent Publications
Bekele W, Gerscovich EO, Naderi S, Bishop J, Gandour-Edwards RF, McGahan JP. Sonography of
an epidermoid inclusion cyst of the thyroid gland. J Ultrasound Med. 2012 Jan;31(1):128-9.
Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ,
Yang X, Davies AM. Phase I study of continuous and intermittent schedules of lapatinib in
Regina F. Gandour-Edwards, M.D., M.H.S., M.S.
combination with vinorelbine in solid tumors. Ann Oncol. 2012 Apr;23(4):1023-9. Epub 2011 Jul
21.
Bailey TL, Fung MA, Gandour-Edwards R, Ellis WG, Schrot RJ. Clinical emergence of
neurometastatic merkel cell carcinoma: a surgical case series and literature review. J Neurooncol.
2011 Mar;102(1):147-55. Epub 2010 Jul 29.
Li B, Bobinski M, Gandour-Edwards R, Farwell DG, Chen AM. Overstaging of cartilage invasion by
multidetector CT scan for laryngeal cancer and its potential effect on the use of organ preservation
with chemoradiation. Br J Radiol. 2011 Jan;84(997):64-9. Epub 2010 Sep 21.
Gerscovich EO, Naderi S, Gandour-Edwards RF. Serous papillary carcinoma of the tunica vaginalis
testis. J Ultrasound Med. 2011 Mar;30(3):418-20.
Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere
White RW. Dual blockade of PKA and NF-?B inhibits H2 relaxin-mediated castrate-resistant
growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2011 Aug;2(4):224-38.
Kim RH, Coates JM, Bowles TL, McNerney G, Sutcliffe J, Jung JU, Gandour-Edwards B., Chuang F,
Bold RJ, Kung HJ. Arginine deaminase as a novel therapy for prostate cancer induces autophagy
and caspase independent apoptosis. Cancer Research 69:700-708. 2009 (PMID: 19147587)
Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI, Lange MK,
Crawford DE. A Phase' Study of Gemcitabine and Capecitabine in Patients with Advanced Renal
Cell Cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol. 2009 May 29. [Epub
ahead of print] (PMID: 19487915)
Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, GandourEdwards R, deVere White RW, Kung HJ. Inappropriate activation of androgen receptor by relaxin
via beta-catenin pathway. Oncogene 27:499-505. 2008 (PMID: 17653089)
You Z, Dong Y, Kong X, Beckett L, Gandour-Edwards R, Melamed J. Midkine is a NF-kB inducible
gene that supports prostate cancer cell survival. BMC Medical Genomics 1:6-10. 2008 (PMID:
18275606)
Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW. Prolonged androgen
receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to
androgen independent growth of prostate cancer cells. The Prostate 68:1816-1826. 2008 (PMID:
18780293)
Gandour-Edwards R, Taylor S, Beckett LA. Tumor grade predicts tumor proportion in fresh frozen
tissue samples for breast cancer research. Cell Preservation Technology 6:1-4. 2008
Gandour-Edwards R, Nguyen H, Castillo M, Soares S. Patient consent: a major obstacle in tissue
banking? Perspectives from the University of California Davis. Cell Preservation Technology 5:151-
Regina F. Gandour-Edwards, M.D., M.H.S., M.S.
154. 2007
Mudryj M, Reay E, Beckett B, Dandekar S, deVere White RW, Gandour-Edwards, R. Novel
p53/p130 axis in bladder carcinoma. Urology 70:608-612. 2007 (PMID: 17905135)
Shi XB, Xue L, Tepper CG, Gandour-Edwards R, Ghosh P, Kung HJ, deVere White R. The
Oncogenic Potential of a Prostate Cancer-Derived Androgen Receptor Mutant. Prostate 2007 May
1; 67(6):591-602. (PMID: 17262801)
Vinall R, Shi XB, Tepper CG, Xue L, Gandour-Edwards R, deVere White RW. The R273H p53
mutation can facilitate the androgen independent growth of LNCaP by a mechanism that involves
relaxin H2 and its cognate receptor LGR7. Oncogene 30:2082-93. 2006 (PMID: 16434975)
You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, deVere
White RW, Reddi AH. Interleukin-17 receptor-like (IL-17RL) gene has anti-apopototic function
associated with androgen independent growth of prostate cancer. Cancer Res 1:175-183. 2006
(PMID: 16397230)
© 2016 UC Regents